Last reviewed · How we verify
Auromid (MOCLOBEMIDE)
At a glance
| Generic name | MOCLOBEMIDE |
|---|---|
| Drug class | Monoamine Oxidase Inhibitors |
| Target | Amine oxidase [flavin-containing] A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Depressive disorder
Common side effects
Drug interactions
- Alpha/Beta Agonists
- Amphetamines
- Indirectly Acting Sympathomimetic Amines
- Selective Serotonin Reuptake Inhibitors
- Serotonin/Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- buspirone
- dextromethorphan
- levodopa
- methyldopa
- mirtazapine
- pethidine
Key clinical trials
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP) (NA)
- Forecast Number of Covid-19 Cases Worldwide
- Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer (PHASE2)
- A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A) (EARLY_PHASE1)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers (PHASE2)
- Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Auromid CI brief — competitive landscape report
- Auromid updates RSS · CI watch RSS